Gholizadeh, N., Mehdipoor, M., Sajadi, H., & Moosavi, M.S. (2016). Palifermin and chlorhexidine mouthwashes in prevention of chemotherapy-induced mucositis in children with acute lymphocytic leukemia: A randomized controlled trial. Journal of Dentistry, 17, 343–347. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136413/pdf/JDS-17-343.pdf
To assess the effectiveness of palifermin in preventing mucositis in children with acute lymphocytic leukemia (ALL) undergoing chemotherapy
A clinical trial of 90 children with ALL who were randomized to receive chlorhexidine or palifermin. One group received 60 mcg/kg palifermin as an IV bolus once daily three days before and three days after chemotherapy. The other group received chlorhexidine mouthwash administered once daily three days before and three days after chemotherapy.
Randomized, controlled trial
The World Health Organization (WHO) Oral Toxicity Scale was used for grading mucositis. The data were analyzed with two-way ANOVA.
The group that used the palifermin had a decreased incidence and severity of chemotherapy-induced mucositis.
Palifermin reduced oral mucositis in children with ALL.
In this study, palifermin has reduced the severity of mucositis in children with ALL who received induction and intensification chemotherapy.